Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder

References

• Faraone SV Sergeant J Gillberg C Biederman J The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003 2 104 113 16946911
   PubMedGoogle Scholar
• Polanczyk G de Lima MS Horta BL Biederman J Rohde LA The worldwide prevalence of ADHD: a systematic review and metaregression analysis Am J Psychiatry 2007 164 942 948 17541055
   PubMed Web of Science ®Google Scholar
• Visser SN Lesesne CA Perou R National estimates and factors associated with medication treatment for childhood attention deficit/hyperactivity disorder Pediatrics 2007 119 S99 S106 17272592
   PubMed Web of Science ®Google Scholar
• Lecendreux M Konofal E Faraone SV Prevalence of attention deficit hyperactivity disorder and associated features among children in France J Atten Disord 2011 15 516 524 20679156
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed Text revision Washington American Psychiatric Association 2000
   Google Scholar
• Biederman J Faraone SV Attention-deficit hyperactivity disorder Lancet 2005 366 237 248 16023516
   PubMed Web of Science ®Google Scholar
• Lecendreux M Konofal E Bouvard M Falissard B Mouren-Simeoni MC Sleep and alertness in children with ADHD J Child Psychol Psychiatry 2002 41 803 812 11039692
   PubMed Web of Science ®Google Scholar
• Golan N Shahar E Ravid S Pillar G Sleep disorders and daytime sleepiness in children with attention-deficit/hyperactive disorder Sleep 2004 27 261 266 15124720
   PubMed Web of Science ®Google Scholar
• Spencer TJ Biederman J Wilens TE Faraone SV Novel treatments for attention-deficit/hyperactivity disorder in children J Clin Psychiatry 2002 63 16 22 12562057
   PubMed Web of Science ®Google Scholar
• Swanson JM Kinsbourne M Nigg J Etiologic subtypes of attention deficit/and hyperactivity disorder: brain imaging, molecular genetic and environmental factors the dopamine hypothesis Neuropsychol Rev 2007 17 39 59 17318414
   PubMed Web of Science ®Google Scholar
• Findling RL Biederman J Wilens TE Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children J Pediatr 2005 147 348 354 16182674
   PubMed Web of Science ®Google Scholar
• Charach A Figueroa M Chen S Ickowicz A Schachar R Stimulant treatment over 5 years: effects on growth J Am Acad Child Adolesc Psychiatry 2006 45 415 421 16601646
   PubMed Web of Science ®Google Scholar
• Faraone SV Lecendreux M Konofal E Growth dysregulation and ADHD: an epidemiologic study of children in France J Atten Disord 2011 15 516 524 20679156
   PubMed Web of Science ®Google Scholar
• Vitiello B Emslie G Clarke G Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample J Clin Psychiatry 2011 72 388 396 21208583
   PubMed Web of Science ®Google Scholar
• Gogerty JH Penberthy C Iorio LC Trapold JH Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4′-chlorophenyl)-2,3-dihydro-5H-imidazo-(2,1-a) isoindole (mazindol) Arch Int Pharmacodyn Ther 1975 214 285 307 1171662
   PubMedGoogle Scholar
• Gogerty JH Trapold JH Chemistry and pharmacology of mazindol Triangle 1976 15 25 36 960214
   PubMedGoogle Scholar
• Hadler AJ Mazindol, a new non-amphetamine anorexigenic agent J Clin Pharmacol New Drugs 1972 12 453 458 4563662
   PubMedGoogle Scholar
• Dugger HA Madrid VO Talbot KC Coombs RA Orwig BA Biotransformation of mazindol. III. Comparison of metabolism in rat, dog, and man Drug Metab Dispos 1979 7 132 137 38082
   PubMed Web of Science ®Google Scholar
• Staples M Microchips and controlled-release drug reservoirs Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010 2 400 417 20564466
   PubMed Web of Science ®Google Scholar
• Conners CK Sitarenios G Parker JD Epstein JN The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity J Abnorm Child Psychol 1998 26 257 268 9700518
   PubMed Web of Science ®Google Scholar
• Conners CK Conners’ Rating Scales – Revised: Technical Manual Toronto Multi-Health System 2000
   Google Scholar
• Retout S Comets E Samson A Mentré F Design in nonlinear mixed effects models: optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates Stat Med 2007 26 5162 5179 17486667
   PubMed Web of Science ®Google Scholar
• Bergstrand M Karlsson MO Handling data below the limit of quantification in mixed effect models AAPS J 2009 11 371 380 19452283
   PubMed Web of Science ®Google Scholar
• Anderson BJ Holford NH Mechanistic basis of using body size and maturation to predict clearance in humans Drug Metab Pharmacokinet 2009 24 25 36 19252334
   PubMed Web of Science ®Google Scholar
• Green B Duffull S Caution when lean body weight is used as a size descriptor for obese subjects Clin Pharmacol Ther 2002 72 743 744 12496756
   PubMed Web of Science ®Google Scholar
• Duffull SB Dooley MJ Green B Poole SG Kirkpatrick CM A standard weight descriptor for dose adjustment in the obese patient Clin Pharmacokinet 2004 43 1167 1178 15568893
   PubMed Web of Science ®Google Scholar
• Lindbom L Ribbing J Jonsson EN Perl-speaks-NONMEM (PsN) – a Perl module for NONMEM related programming Comput Methods Programs Biomed 2004 75 85 94 15212851
   PubMed Web of Science ®Google Scholar
• Brendel K Comets E Laffont C Laveille C Mentré F Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide Pharm Res 2006 23 2036 2049 16906454
   PubMed Web of Science ®Google Scholar
• Jonsson EN Karlsson MO Xpose – an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 1999 58 51 64 10195646
   PubMed Web of Science ®Google Scholar
• Comets E Brendel K Mentré F Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R Comput Methods Programs Biomed 2008 90 154 166 18215437
   PubMed Web of Science ®Google Scholar
• de Felice EA Chaykin LB Cohen A Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity Curr Ther Res 1973 15 358 366 4198296
   PubMed Web of Science ®Google Scholar
• Aeberli P Eden P Gogerty JH Houlihan WJ Penberthy C 5-Aryl-2,3-dihydro-5H-imidazo[2,1-a] isoindols. A novel class of anorectic agents J Med Chem 1975 18 177 181 804553
   PubMed Web of Science ®Google Scholar
• Inoue S Clinical studies with mazindol Obes Res 1995 Suppl 4 549S 552S 8697057
   PubMedGoogle Scholar
• Bray GA A concise review on the therapeutics of obesity Nutrition 2000 16 953 960 11054601
   PubMed Web of Science ®Google Scholar
• Parkes JD Baraitser M Marsden CD Asselman P Natural history, symptoms and treatment of the narcoleptic syndrome Acta Neurol Scandinav 1975 52 337 353 19899267
   PubMed Web of Science ®Google Scholar
• Parkes JD Schachter M Mazindol in the treatment of narcolepsy Acta Neurol Scand 1979 60 250 254 525256
   PubMed Web of Science ®Google Scholar
• Vespignani H Weber M Atlas P Barroche G Value of mazindol in Gélineau’s disease. A propos of 10 cases Rev Electroencephalogr Neurophysiol Clin 1986 16 317 322 French 3809694
   PubMedGoogle Scholar
• Iijima S Sugita Y Teshima Y Hishikawa Y Therapeutic effects of mazindol on narcolepsy Sleep 1986 9 265 268 3704452
   PubMed Web of Science ®Google Scholar
• Alvarez B Dahlitz M Grimshaw J Parkes JD Mazindol in long-term treatment of narcolepsy Lancet 1991 337 1293 1294 1674093
   PubMed Web of Science ®Google Scholar
• Kim SS Lee HW Lee KT Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 2009 877 1011 1016
   PubMed Web of Science ®Google Scholar
• Wigal SB Jun A Wong AA Stehli A Steinberg-Epstein R Lerner MA Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate? Postgrad Med 2010 122 27 34 20861585
   PubMed Web of Science ®Google Scholar
• Pichini S Papaseit E Joya X Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics Ther Drug Monit 2009 31 283 318 19363463
   PubMed Web of Science ®Google Scholar
• Gilbert DL Wang Z Sallee FR Dopamine transporter genotype influences the physiological response to medication in ADHD Brain 2006 129 2038 2046 16760197
   PubMed Web of Science ®Google Scholar
• Joober R Grizenko N Sengupta S Dopamine transporter 3′-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate Neuropsychopharmacology 2007 32 1370 1376 17063150
   PubMed Web of Science ®Google Scholar
• Nittur N Konofal E Dauvilliers Y Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review Sleep Med 2013 14 30 36 23036267
   PubMed Web of Science ®Google Scholar
• Stiefel G Besag FM Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder Drug Saf 2010 33 821 842 20812768
   PubMed Web of Science ®Google Scholar
• Desnuelle C Serratrice G N’guyen VK Richelme C Pinsard N A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children Arch Fr Pediatr 1989 46 759 765 French 2697199
   PubMedGoogle Scholar